MTND4P21

Across TCGA pan-cancer cohorts, MTND4P21 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MTND4P21 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher MTND4P21 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND4P21 expression acts as an unfavorable survival marker, although some lineages such as CESC and READ show a favorable association.

MESO, COAD, and LUSC are the cancer types where MTND4P21 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	II,III,IV	0.104	0.417	<.001	45	view →
COAD	OS	Tertile	IV	0.174	0.757	<.001	36	view →
LUSC	DFS	Tertile	III,IV	0.228	0.540	.007	33	view →
CESC	OS	Tertile	All	0.941	0.774	.028	30	view →
KIRC	DFS	Tertile	All	0.423	0.667	.001	24	view →
HNSC	OS	Tertile	IV	0.283	0.660	.003	21	view →
READ	OS	Tertile	All	1.000	0.506	.013	12	view →
LGG	DFS	Tertile	All	0.353	0.427	.029	9	view →
ACC	DFS	Tertile	All	0.731	0.301	.022	8	view →
STAD	OS	Median	III,IV	0.510	0.225	.019	6	view →
ESCA	DFS	Quartile	All	0.487	0.667	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MTND4P21–MESO (DFS)

Open the MESO breakdown →